Cormorant Asset Management, LP and Bihua Chen filed Amendment No. 5 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 4,500,000 shares of Cabaletta Bio, Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting persons: Cormorant Asset Management, LP, a Delaware limited partnership, and Bihua Chen jointly filed as the two reporting persons.
  • Shares beneficially owned: Both reporting persons each report aggregate beneficial ownership of 4,500,000 shares of Cabaletta Bio common stock.
  • Percent of class: The 4,500,000 shares represent 2.65% of Cabaletta Bio's outstanding common stock, according to the filing.
  • Voting and dispositive power: Both reporting persons report 0 shares with sole voting or sole dispositive power, and 4,500,000 shares with shared voting and shared dispositive power.
  • Share count basis: The 2.65% figure is calculated using 169,545,445 shares outstanding as of August 7, 2026, per Cabaletta Bio's quarterly report filed August 13, 2026.
  • Event date: The date of event requiring this filing is reported as September 30, 2026.

Cormorant's Amended Ownership Position in Cabaletta Bio

Cormorant Asset Management, LP, described in the filing as a Delaware limited partnership that serves as investment adviser to certain funds referred to as the "Cormorant Funds," and Bihua Chen, a United States citizen who signed as Managing Member, together submitted this amendment to their Schedule 13G covering common stock of Cabaletta Bio, Inc. (NASDAQ:CABA). Cabaletta Bio is a clinical-stage biopharmaceutical company headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA 19104, according to the issuer address stated in the filing. The shares reported are held directly by the Cormorant Funds, with both Cormorant Asset Management, LP and Bihua Chen reporting beneficial ownership on that basis.

According to the filing, all 4,500,000 shares are held with shared voting power and shared dispositive power, with neither reporting person holding any shares under sole voting or sole dispositive power. The filing states that the percentages reported are calculated based on 169,545,445 shares of Cabaletta Bio common stock outstanding as of August 7, 2026, as disclosed in the issuer's quarterly report for the period ended June 30, 2026, filed with the SEC on August 13, 2026. The filing further notes that it "should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein."

The certifications included in the filing state that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." This is Amendment No. 5 to the original Schedule 13G, with the joint filing statement incorporated by reference to the joint filing statement included in the Schedule 13G filed by the reporting persons on August 14, 2025.

What Was Disclosed

Cormorant Asset Management, LP and Bihua Chen disclosed a combined beneficial ownership of 4,500,000 shares of Cabaletta Bio, Inc. common stock, equal to 2.65% of the class, as of a September 30, 2026 triggering event, via Amendment No. 5 to their Schedule 13G filed November 16, 2026.